Molecular Formula | C22H26O6.H2O |
Molar Mass | 404.46 |
Solubility | 10 mM in DMSO |
Storage Condition | -20℃ |
In vitro study | Tofogliflozin is a potent and selective inhibitor of SGLT2, which is 2900 times more selective for SGLT2 than for sglt1. Tofogliflozin inhibited glucose entry into tubular epithelial cells in a concentration-dependent manner. tofogliflozin inhibits high glucose-induced ROS production, MCP-1 can induce apoptosis of tubular epithelial cells and induce NAC antioxidant. |
In vivo study | Single oral administration in Zucker Diabetic Rats can reduce blood glucose levels and increase the clearance of dirty glucose. Treatment with Tofogliflozin for 4 weeks significantly improved glucose tolerance in db/db mice. And losartan has no secondary effect. The treatment of Tofogliflozin can reduce the glucose reabsorption threshold in db/db mice, increase UGE and reduce PG; The treatment of Tofogliflozin can significantly and dose-dependently increase the total beta cell number. This means that the reduction of beta cells is prevented. Tofogliflozin inhibits plasma glucose and glycated Hb, maintains pancreatic beta cell mass, and plasma insulin levels. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.472 ml | 12.362 ml | 24.725 ml |
5 mM | 0.494 ml | 2.472 ml | 4.945 ml |
10 mM | 0.247 ml | 1.236 ml | 2.472 ml |
5 mM | 0.049 ml | 0.247 ml | 0.494 ml |